Needham, MA—Construction is now underway for the new Beth Israel Deaconess Cancer Center & Surgical Pavilion after Beth Israel Deaconess Medical Center (BIDMC) and Beth Israel Deaconess Hospital-Needham (BID-Needham) broke ground today for the building which is expected to open in summer 2014.
This comprehensive cancer center and surgical pavilion will consolidate BIDMC’s west suburban cancer services into a new, state-of-the-art facility. The new surgical area will provide the ability for patients to have more advanced surgeries closer to home.
“This will be a very patient-centered facility,” said BID-Needham President and CEO John Fogarty. “Patients and clinicians have worked side by side with the architects for months to design the ideal patient experience. The result is a plan that consolidates all cancer services on one floor and a new surgical center on the second floor which allows for more advanced surgeries including cancer, colorectal, orthopaedic, urology, otolaryngology and general surgery.”
The three-story, 30,000-square foot building, designed by JACA Architects and being constructed by BOND, will be located on the footprint of BID-Needham’s former administration building, which was ceremoniously demolished last week. In addition to the new building, a new parking area is being built where parking will continue to be free for all patient and visitors.
“This collaboration between BIDMC and Needham offers a unique opportunity to upgrade and expand cancer and surgical services already being offered in Needham to our patients in the western suburbs,” said Kevin Tabb MD, BIDMC’s President and CEO. “It is the latest example of our commitment to provide the right care in the right place at the right time.”
In the new building, BIDMC will offer patients a full array of cancer care which will include: advanced imaging systems; six new infusion bays; a radiation oncology suite which will include a state-of-the-art linear accelerator to facilitate the delivery of advanced conformal radiation therapy; and access to cutting-edge clinical trials and novel treatments.
“BIDMC already offers coordinated care from extraordinary clinicians in the service of individualized medicine,” said Lowell Schnipper, MD, clinical director of the BIDMC Cancer Center. “This new facility will enable us to provide patients the same world class-care available without them having to travel to and park in downtown Boston.”
The $24 million cost of the cancer center and surgical pavilion will be financed by a combination of community-raised capital campaign funds and significant investments by BID–Needham and BIDMC. BID–Needham will raise $6 million to make this cancer center and surgical pavilion a reality.
“This is an incredible day,” commented Richard W. Davis, Chair of the Board of Trustees, BID-Needham. “We could not accomplish this without the collaboration of the two hospitals and the community’s ongoing support. I am thrilled to be able to be part of such an important chapter in our history and the mission to keep our commitment to provide easy access to health care close to home.”
This project represents Phase II of a dedicated plan to improve and expand care available to patients in the western suburbs. In October 2009, BID-Needham opened a new emergency department and a new inpatient wing.
“BIDMC is proud to partner with BID-Needham in this project,” said Stephen Kay, chair of the BIDMC Board of Directors. “This new facility makes high- quality cancer and surgical care even more accessible.”
BIDMC is recognized by US News & World Report as one of the nation’s top hospitals in cancer care. In 2010, BIDMC joined with Commonwealth Hematology-Oncology, the largest community-based private cancer practice in New England, to expand the reach of BIDMC’s services into the community. Together, BIDMC and CHO have more than 22 physicians in 11 locations and infusion centers in communities across Eastern Massachusetts
The BIDMC Cancer Center is one of the preeminent clinical and research cancer programs in the country, offering the best in early diagnosis, leading edge treatments and personalized care plans. Multidisciplinary teams offer 18 specialty programs, such as those focusing on breast cancer, prostate cancer and biologic therapy. As a founding member of the Dana-Farber/Harvard Cancer Center, BIDMC patients benefit from access to a broad range of clinical trials. The Cancer Center is a member of the Eastern Cooperative Oncology Group (ECOG), and an active participant in many of the National Cancer Institute’s Specialized Programs of Research Excellence (SPORE). It was the first program in Massachusetts, to receive the Outstanding Achievement Award from the Commission on Cancer of the American College of Surgeons.
The medical center has been home to some of the nation’s top cancer researchers. In 2011, Pier Paolo Pandolfi, MD, PhD received Pezcoller Foundation-AACR (American Association of Cancer Research) International Award for Cancer Research. Lewis Cantley, PhD, who discovered of promising avenue for the development of personalized cancer therapies in his BIDMC lab, received the Pezcoller award in 2005.
BIDMC was the first center in New England – and one of only a select number of hospitals in the country – to offer CyberKnife, a dynamic radiation therapy system that is a noninvasive, radiosurgical alternative to open surgery for cancerous and other tumors. BIDMC’s Keith C. Field CyberKnife Center uses precise image-guidance and a multi-jointed robotic arm to deliver concentrated beams of radiation from multiple directions.
BIDMC also offers advanced imaging systems – including Boston’s first PET/CT scanner – for early cancer detection, less invasive breast imaging, advanced gastrointestinal diagnostic techniques, virtual colonoscopy and more.
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and currently ranks third in National Institutes of Health funding among independent hospitals nationwide.
BIDMC has a network of community partners that includes Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Anna Jaques Hospital, Lawrence General Hospital, Commonwealth Hematology-Oncology, Beth Israel Deaconess HealthCare, Community Care Alliance, Atrius Health and Hebrew SeniorLife. BIDMC is also clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.
Beth Israel Deaconess Hospital-Needham has received national and local recognition for its extraordinary stroke care. It was recently named to Harvard Pilgrim’s Hospital Honor Roll which distinguishes the top adult, acute care hospitals in the nation. BID-Needham is part of the CareGroup System which Thomson Reuters named one of the five best large health systems in the United States. Boston magazine recognized BID-Needham as one of the eight best community hospitals in Massachusetts. The hospital received tremendous community support when an editorial in a local newspaper urged everyone in the community “to support the hospital that provides first-class medical care in your own community. Needham is lucky to have Beth Israel Deaconess right in its backyard.”
A licensed 56-bed acute care community hospital, BID-Needham has served the residents of Needham, Dedham, Dover, Medfield, Newton, Wellesley, Westwood for and surrounding communities for more than 100 years. This community hospital, previously known as The Glover Hospital, joined Beth Israel Deaconess Medical Center in 2002. The hospital provides comprehensive inpatient and outpatient services, complete diagnostic facilities, and a brand new, award-winning Emergency Department. For more information, visit www.bidneedham.org.